LONDON — The U.K.'s FTSE 100 closed higher by a whisker to keep its winning streak intact and be on par with its best run in 2017. Most other European markets closed for the May 1 holiday.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills — the latest in a series of moves by the Danish drugmaker as it hopes to ...

Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1 ...

Novo Nordisk A/S is partnering with U.S. biotech Septerna Inc. on the development of oral pills for obesity in a deal potentially worth up to $2.2 billion. The two companies will start with four ...

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...

Meanwhile, the Ultimate 2 Bluetooth will replace the original as GameSpot's pick for the best third-party Switch controller, and we're eager to see how it stacks up with the Switch 2 Pro Controller.

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. Earlier this year, the Danish pharma traded barbs with telehealth provider Hims & Hers over the ...

FRANKFURT, Germany — (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with ...

Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to stem sales of copies of its popular weight-loss drug and expand access ...